Zentalis Pharmaceuticals, Inc. (ZNTL)
1.695
+0.02
(+0.89%)
USD |
NASDAQ |
Nov 13, 16:00
1.695
0.00 (0.00%)
After-Hours: 19:59
Zentalis Pharmaceuticals Enterprise Value : -27.11M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | -27.11M |
| November 11, 2026 | -6.472M |
| November 10, 2026 | -15.32M |
| November 09, 2026 | -21.21M |
| November 06, 2026 | -23.18M |
| November 05, 2026 | -24.16M |
| November 04, 2026 | -19.25M |
| November 03, 2026 | -17.28M |
| November 02, 2026 | -10.40M |
| October 30, 2026 | 0.4058M |
| October 29, 2026 | 3.354M |
| October 28, 2026 | 10.23M |
| October 27, 2026 | 2.371M |
| October 26, 2026 | 11.21M |
| October 23, 2026 | 24.97M |
| October 22, 2026 | 44.62M |
| October 21, 2026 | 39.71M |
| October 20, 2026 | 42.66M |
| October 19, 2026 | 33.81M |
| October 16, 2026 | 17.11M |
| October 15, 2026 | 27.92M |
| October 14, 2026 | 35.78M |
| October 13, 2026 | 43.64M |
| October 12, 2026 | 55.43M |
| October 09, 2026 | 67.22M |
| Date | Value |
|---|---|
| October 08, 2026 | 54.45M |
| October 07, 2026 | 58.38M |
| October 06, 2026 | 70.17M |
| October 05, 2026 | 80.98M |
| October 02, 2026 | 55.43M |
| October 01, 2026 | 63.78M |
| September 30, 2026 | 80.00M |
| September 29, 2026 | 57.66M |
| September 28, 2026 | 49.42M |
| September 25, 2026 | 56.59M |
| September 24, 2026 | 60.17M |
| September 23, 2026 | 68.77M |
| September 22, 2026 | 83.82M |
| September 21, 2026 | 80.24M |
| September 18, 2026 | 85.97M |
| September 17, 2026 | 83.82M |
| September 16, 2026 | 85.25M |
| September 15, 2026 | 87.40M |
| September 14, 2026 | 113.92M |
| September 11, 2026 | 114.64M |
| September 10, 2026 | 120.37M |
| September 09, 2026 | 135.42M |
| September 08, 2026 | 151.91M |
| September 04, 2026 | 149.04M |
| September 03, 2026 | 157.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ARS Pharmaceuticals, Inc. | 365.40M |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
| Savara, Inc. | 870.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.82M |
| Total Expenses (Quarterly) | 28.82M |
| EPS Diluted (Quarterly) | -0.3406 |
| Earnings Yield | -113.7% |
| Normalized Earnings Yield | -114.45 |